Dupilumab Effects Against Aeroallergen Challenge

This study is testing whether dupilumab — an injectable medication already approved for eczema and asthma — can reduce nose and lung reactions in people with perennial allergic rhinitis (year-round nasal allergies, typically to dust mites) and asthma when they are exposed to allergens in a controlled clinical setting. **You may be eligible if...** - You are between 18 and 65 years old - You have had perennial nasal allergy symptoms (to dust mites) for at least 2 years - You have asthma with documented reversibility on breathing tests - You have a positive allergy skin test to dust mites within the past 2 years - You are a non-smoker or former light smoker (less than 20 pack-year history, none in the past year) **You may NOT be eligible if...** - You have chronic lung disease other than asthma (e.g., COPD, pulmonary fibrosis) - You have atopic dermatitis (eczema) - You have eye disease unrelated to allergies - You require home oxygen - You have a history of severe nasal congestion or nasal polyps requiring specific treatments Talk to your doctor to see if this trial is right for you.